NewAmsterdam Pharma (NASDAQ:NAMS) Receives Consensus Rating of “Buy” from Analysts
Shares of NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) have been given an average rating of “Buy” by the six analysts that are currently covering the company, MarketBeat.com reports. Six equities research analysts have rated the stock with a buy recommendation. The average twelve-month price target among analysts that have updated their coverage on the […]
More Stories
Weather, Power, and Water Issues Persist in Los Angeles’ Eaton Fire Area
By Beige Luciano-Adams LOS ANGELES—Residents eager to return home and survey vast damage wrought by the Eaton Canyon Fire in...
Titanium Transportation Group (CVE:TTR) Share Price Passes Below 50 Day Moving Average – Should You Sell?
Titanium Transportation Group Inc. (CVE:TTR – Get Free Report)’s share price passed below its 50 day moving average during trading...
Invesco Aerospace & Defense ETF (NYSEARCA:PPA) Stock Price Passes Below 50-Day Moving Average – Here’s Why
Invesco Aerospace & Defense ETF (NYSEARCA:PPA – Get Free Report) shares crossed below its fifty day moving average during trading...
ImmuPharma (LON:IMM) Shares Up 4.9% – What’s Next?
ImmuPharma plc (LON:IMM – Get Free Report)’s share price shot up 4.9% during mid-day trading on Saturday . The company...
Omineca Mining and Metals (CVE:OMM) Stock Price Down 15.4% – Here’s Why
Omineca Mining and Metals Ltd. (CVE:OMM – Get Free Report)’s stock price traded down 15.4% on Saturday . The company...
China Shenhua Energy (OTCMKTS:CSUAY) Stock Passes Below 50 Day Moving Average – Here’s What Happened
Shares of China Shenhua Energy Company Limited (OTCMKTS:CSUAY – Get Free Report) passed below its 50 day moving average during...